Compare Divis Laboratories with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs STRIDES PHARMA SCIENCE - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES STRIDES PHARMA SCIENCE DIVIS LABORATORIES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 54.2 46.7 116.0% View Chart
P/BV x 14.5 2.2 664.6% View Chart
Dividend Yield % 0.4 0.2 189.2%  

Financials

 DIVIS LABORATORIES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
DIVIS LABORATORIES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,6391,147 142.9%   
Low Rs1,115642 173.7%   
Sales per share (Unadj.) Rs186.3317.2 58.7%  
Earnings per share (Unadj.) Rs51.07.8 649.6%  
Cash flow per share (Unadj.) Rs57.325.1 228.8%  
Dividends per share (Unadj.) Rs16.002.00 800.0%  
Dividend yield (eoy) %1.20.2 519.6%  
Book value per share (Unadj.) Rs261.8274.3 95.5%  
Shares outstanding (eoy) m265.4789.50 296.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.42.8 262.1%   
Avg P/E ratio x27.0114.0 23.7%  
P/CF ratio (eoy) x24.035.7 67.3%  
Price / Book Value ratio x5.33.3 161.3%  
Dividend payout %31.425.5 123.2%   
Avg Mkt Cap Rs m365,59280,058 456.7%   
No. of employees `00011.82.5 472.6%   
Total wages/salary Rs m5,4234,341 124.9%   
Avg. sales/employee Rs Th4,175.111,325.8 36.9%   
Avg. wages/employee Rs Th457.71,731.4 26.4%   
Avg. net profit/employee Rs Th1,141.8280.1 407.7%   
INCOME DATA
Net Sales Rs m49,46328,394 174.2%  
Other income Rs m1,556941 165.5%   
Total revenues Rs m51,01929,334 173.9%   
Gross profit Rs m18,7183,965 472.0%  
Depreciation Rs m1,6891,540 109.6%   
Interest Rs m351,962 1.8%   
Profit before tax Rs m18,5511,403 1,322.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m5,02397 5,162.7%   
Profit after tax Rs m13,527702 1,926.7%  
Gross profit margin %37.814.0 271.0%  
Effective tax rate %27.16.9 390.5%   
Net profit margin %27.32.5 1,106.0%  
BALANCE SHEET DATA
Current assets Rs m46,50124,836 187.2%   
Current liabilities Rs m8,46818,993 44.6%   
Net working cap to sales %76.920.6 373.7%  
Current ratio x5.51.3 420.0%  
Inventory Days Days13171 184.3%  
Debtors Days Days86113 75.7%  
Net fixed assets Rs m25,79734,289 75.2%   
Share capital Rs m531895 59.3%   
"Free" reserves Rs m68,96223,651 291.6%   
Net worth Rs m69,49324,546 283.1%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m80,38365,437 122.8%  
Interest coverage x531.01.7 30,962.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.4 141.8%   
Return on assets %16.94.1 414.4%  
Return on equity %19.52.9 680.5%  
Return on capital %26.76.9 387.9%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23815,697 262.7%   
Fx outflow Rs m12,405735 1,686.9%   
Net fx Rs m28,83314,962 192.7%   
CASH FLOW
From Operations Rs m9,5431,871 510.1%  
From Investments Rs m-6,8545,826 -117.6%  
From Financial Activity Rs m-2,459-10,157 24.2%  
Net Cashflow Rs m230-2,615 -8.8%  

Share Holding

Indian Promoters % 52.0 27.7 187.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 37.8 31.2%  
FIIs % 19.0 8.6 220.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 25.9 66.4%  
Shareholders   31,796 56,241 56.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ELDER PHARMA  WOCKHARDT  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Apr 19, 2021 03:36 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS